10 completed, 6 active not recruiting, 6 recruiting. 19 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 8, Recruiting 6, Active not recruiting 5 |
| Phase 1 | 8 | Completed 6, Active not recruiting 2 |
Follow Grade 3a Follicular Lymphoma: new trials by email Literature Review of Grade 3a Follicular Lymphoma trials Research Report on Grade 3a Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 22 | 2025-11-17 | 2026-06-04 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Washington | 20 | 2024-08-29 | 2026-08-27 |
| Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma Zanubrutinib, Rituximab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2024-07-10 | 2026-07-20 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Ibrutinib, Obinutuzumab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma | Phase 2 | Active not recruiting | University of California, Davis | 40 | 2021-02-24 | 2026-04-13 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma Acalabrutinib, Lenalidomide, Rituximab - Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2020-07-16 | 2026-11-02 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Anti-OX40 Antibody BMS 986178, Laboratory Biomarker Analysis, Radiation Therapy - B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Ronald Levy | 14 | 2018-04-09 | 2024-12-11 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2018-01-23 | 2026-07-08 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Lenalidomide, Obinutuzumab - Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2016-12-06 | 2025-06-08 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 21 | 2016-11-07 | 2024-10-16 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2016-04-11 | 2024-09-24 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
Showing 20 of 22. Sign in to see all of them.
Lymphoma, Follicular (19) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Mantle-Cell (6) · Lymphoma, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Waldenstrom Macroglobulinemia (2) · Anemia (1) · Fatigue (1) · Fever (1) · Leukemia, Hairy Cell (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoma (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Lymphoproliferative Disorders (18) · Lymphoma, Non-Hodgkin (16) · Lymphoma, B-Cell (6) · Hematologic Diseases (5) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · DNA Virus Infections (3) · Disease Attributes (3)
obinutuzumab (9) · Lenalidomide (7) · Magnetic Resonance Spectroscopy (6) · ibrutinib (6) · Rituximab (4) · Biopsy (3) · CT-P10 (3) · Specimen Handling (3) · acalabrutinib (3) · venetoclax (3) · Bendamustine Hydrochloride (2) · Radiation (2) · Radiotherapy (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bortezomib (1)
University of Washington (5) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · Alexey Danilov, MD (1) · Beth Christian (1) · Chinese PLA General Hospital (1) · David Bond, MD (1) · Emory University (1) · Kami Maddocks (1) · Robert Lowsky (1) · Ronald Levy (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of California, Davis (1)
United States (21) · Canada (1) · China (1) · Singapore (1)
Ajay Gopal (2) · Loretta J Nastoupil (2) · Mengyang Di, MD, PhD (2) · Ronald Levy (2) · Beth Christian, MD (1) · Craig Okada, M.D. (1) · David Bond, MD (1) · Jonathon B Cohen, MD, MS (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1) · Kristie A Blum (1) · Loretta Nastoupil (1) · Michael Khodadoust (1) · Nancy L Bartlett (1) · Paolo Strati (1)
PMID 34780125, PMID 29074501, PMID 31174236, PMID 34196037, PMID 35135810, PMID 35787017, PMID 37939259, PMID 37985359, PMID 39161543, PMID 40517417, PMID 42600120
R35CA197353 (2), U10CA180821 (2), N01CM00032 (1), N01CM00099 (1), P30CA015083 (1), P30CA016058 (1), P30CA093373 (1), P30CA138292 (1), U10CA031946 (1), U10CA180888 (1)